The Scottish NHS is set to offer a weight-loss jab, Wegovy, to patients at risk of heart attacks and strokes, marking a significant step in the battle against cardiovascular disease. This decision comes as a response to the alarming statistics surrounding cardiovascular diseases in Scotland, which account for over a quarter of all deaths and are the second leading cause of mortality after cancer. The Scottish Medicines Consortium (SMC) has approved semaglutide, the active ingredient in Wegovy, as a treatment alongside diet and exercise for patients who are overweight and have cardiovascular disease. This approval follows a similar move in England, where the jab was accepted for use on the NHS in April, with a summer rollout expected. The eligibility criteria for Scottish patients include a Body Mass Index (BMI) of 27 or higher and health issues that increase the risk of strokes and heart attacks. The jab works by suppressing appetite and slowing down food digestion, leading to weight loss. However, it's important to note that some individuals may experience side effects such as bloating, nausea, or discomfort. Patients can self-administer the drug at home using a special pen injector device. The effectiveness of Wegovy is supported by drug trials that demonstrate a significant reduction in the risk of future heart and circulation problems, even before substantial weight loss occurs. This suggests that the drug directly impacts the heart and blood vessels, not just through weight loss, according to the National Institute for Health and Care Excellence. The potential impact of this decision is profound, as experts estimate that cardiovascular disease could be prevented in about seven out of ten cases based on the best evidence. The Royal College of Physicians of Edinburgh has expressed strong support for the use of weight-loss jabs, with Dr. Mark Strachan describing them as some of the most effective medicines he has ever encountered. He criticized the Scottish NHS for its slow adoption of these jabs, suggesting that a similar delay in breast cancer treatment would spark a national outcry. The SMC's acceptance of Wegovy is a crucial step in addressing the cardiovascular health crisis in Scotland, offering a promising treatment option for patients at high risk. However, the challenge now lies in ensuring widespread access and effective implementation of this treatment, which will require careful planning and collaboration between healthcare providers and policymakers.
